Skip to main content
. Author manuscript; available in PMC: 2011 Mar 8.
Published in final edited form as: Biomacromolecules. 2010 Mar 8;11(3):754–761. doi: 10.1021/bm901352v

Figure 1.

Figure 1

3D maximum intensity projection images for G2 (a) and CLT1 peptide targeted G2 (b), 2D axial T1-weighted spin-echo images of tumor tissue of the G2 (c) and peptide targeted G2 (d) nanoglobular MRI contrast agents intravenously administered at 0.03 mmol-Gd/kg in nu/nu female nude mice bearing MDA MB-231 tumor xenografts. Arrows indicate tumor.